176 related articles for article (PubMed ID: 33131142)
21. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6) are associated with long term tramadol treatment-induced oxidative damage and hepatotoxicity.
Arafa MH; Atteia HH
Toxicol Appl Pharmacol; 2018 May; 346():37-44. PubMed ID: 29555325
[TBL] [Abstract][Full Text] [Related]
22. Post-mortem SNP analysis of CYP2D6 gene reveals correlation between genotype and opioid drug (tramadol) metabolite ratios in blood.
Levo A; Koski A; Ojanperä I; Vuori E; Sajantila A
Forensic Sci Int; 2003 Jul; 135(1):9-15. PubMed ID: 12893130
[TBL] [Abstract][Full Text] [Related]
23. Different Pharmacokinetics of Tramadol,
Neskovic N; Mandic D; Marczi S; Skiljic S; Kristek G; Vinkovic H; Mraovic B; Debeljak Z; Kvolik S
Front Pharmacol; 2021; 12():656748. PubMed ID: 33935773
[No Abstract] [Full Text] [Related]
24. Quantification of drugs in plasma without primary reference standards by liquid chromatography-chemiluminescence nitrogen detection: application to tramadol metabolite ratios.
Ojanperä S; Rasanen I; Sistonen J; Pelander A; Vuori E; Ojanperä I
Ther Drug Monit; 2007 Aug; 29(4):423-8. PubMed ID: 17667796
[TBL] [Abstract][Full Text] [Related]
25. Postmenstrual age and CYP2D6 polymorphisms determine tramadol o-demethylation in critically ill neonates and infants.
Allegaert K; van Schaik RH; Vermeersch S; Verbesselt R; Cossey V; Vanhole C; van Fessem M; de Hoon J; van den Anker JN
Pediatr Res; 2008 Jun; 63(6):674-9. PubMed ID: 18317231
[TBL] [Abstract][Full Text] [Related]
26. Assessment of tramadol pharmacokinetics in correlation with CYP2D6 and clinical symptoms.
Ahmadimanesh M; Naeini MB; Rouini MR; Shadnia S; Ghazi-Khansari M
Drug Metab Pers Ther; 2020 Jun; 35(2):. PubMed ID: 32681776
[TBL] [Abstract][Full Text] [Related]
27. Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation.
Abdel-Rahman SM; Leeder JS; Wilson JT; Gaedigk A; Gotschall RR; Medve R; Liao S; Spielberg SP; Kearns GL
J Clin Pharmacol; 2002 Jan; 42(1):24-9. PubMed ID: 11808821
[TBL] [Abstract][Full Text] [Related]
28. Pharmacogenetic aspects of tramadol pharmacokinetics and pharmacodynamics after a single oral dose.
Bastami S; Haage P; Kronstrand R; Kugelberg FC; Zackrisson AL; Uppugunduri S
Forensic Sci Int; 2014 May; 238():125-32. PubMed ID: 24709712
[TBL] [Abstract][Full Text] [Related]
29. Miotic action of tramadol is determined by CYP2D6 genotype.
Slanar O; Nobilis M; Kvetina J; Mikoviny R; Zima T; Idle JR; Perlík F
Physiol Res; 2007; 56(1):129-136. PubMed ID: 16497087
[TBL] [Abstract][Full Text] [Related]
30. The effects of tramadol on static and dynamic pupillometry in healthy subjects--the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status.
Fliegert F; Kurth B; Göhler K
Eur J Clin Pharmacol; 2005 Jun; 61(4):257-66. PubMed ID: 15906019
[TBL] [Abstract][Full Text] [Related]
31. Population pharmacokinetic modeling of tramadol and its O-desmethyl metabolite in plasma and breast milk.
Salman S; Sy SK; Ilett KF; Page-Sharp M; Paech MJ
Eur J Clin Pharmacol; 2011 Sep; 67(9):899-908. PubMed ID: 21394525
[TBL] [Abstract][Full Text] [Related]
32. Relationship of CYP2D6 genetic polymorphisms and the pharmacokinetics of tramadol in Chinese volunteers.
Li Q; Wang R; Guo Y; Wen S; Xu L; Wang S
J Clin Pharm Ther; 2010 Apr; 35(2):239-47. PubMed ID: 20456744
[TBL] [Abstract][Full Text] [Related]
33. CYP2D6 polymorphism in relation to tramadol metabolism: a study of faroese patients.
Halling J; Weihe P; Brosen K
Ther Drug Monit; 2008 Jun; 30(3):271-5. PubMed ID: 18520597
[TBL] [Abstract][Full Text] [Related]
34. Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers.
Pedersen RS; Damkier P; Brøsen K
Eur J Clin Pharmacol; 2006 Jul; 62(7):513-21. PubMed ID: 16763825
[TBL] [Abstract][Full Text] [Related]
35. Enantioselective analysis of unbound tramadol, O-desmethyltramadol and N-desmethyltramadol in plasma by ultrafiltration and LC-MS/MS: application to clinical pharmacokinetics.
de Moraes NV; Lauretti GR; Napolitano MN; Santos NR; Godoy AL; Lanchote VL
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Jan; 880(1):140-7. PubMed ID: 22173007
[TBL] [Abstract][Full Text] [Related]
36. O-demethylation of tramadol in the first months of life.
Allegaert K; Van den Anker JN; Verbesselt R; de Hoon J; Vanhole C; Tibboel D; Devlieger H
Eur J Clin Pharmacol; 2005 Dec; 61(11):837-42. PubMed ID: 16283273
[TBL] [Abstract][Full Text] [Related]
37. Simultaneous determination of tramadol, O-desmethyltramadol and N-desmethyltramadol in human urine by gas chromatography-mass spectrometry.
El-Sayed AA; Mohamed KM; Nasser AY; Button J; Holt DW
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 May; 926():9-15. PubMed ID: 23542669
[TBL] [Abstract][Full Text] [Related]
38. Effects of type 1 and type 2 diabetes on the pharmacokinetics of tramadol enantiomers in patients with neuropathic pain phenotyped as cytochrome P450 2D6 extensive metabolizers.
de Moraes NV; Lauretti GR; Lanchote VL
J Pharm Pharmacol; 2014 Sep; 66(9):1222-30. PubMed ID: 24717054
[TBL] [Abstract][Full Text] [Related]
39. Enantioselective determination of tramadol and its main phase I metabolites in human plasma by high-performance liquid chromatography.
Ardakani YH; Mehvar R; Foroumadi A; Rouini MR
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Mar; 864(1-2):109-15. PubMed ID: 18282749
[TBL] [Abstract][Full Text] [Related]
40. Physiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation.
T'jollyn H; Snoeys J; Vermeulen A; Michelet R; Cuyckens F; Mannens G; Van Peer A; Annaert P; Allegaert K; Van Bocxlaer J; Boussery K
AAPS J; 2015 Nov; 17(6):1376-87. PubMed ID: 26209290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
